Last 35.30 NOK
Change Today -0.60 / -1.67%
Volume 260.2K
PHO On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:51 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

photocure asa (PHO) Snapshot

Open
36.00 NOK
Previous Close
35.90 NOK
Day High
36.00 NOK
Day Low
34.50 NOK
52 Week High
01/12/15 - 39.00 NOK
52 Week Low
11/4/14 - 17.70 NOK
Market Cap
755.2M
Average Volume 10 Days
26.8K
EPS TTM
-0.78 NOK
Shares Outstanding
21.4M
EX-Date
05/23/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOTOCURE ASA (PHO)

Related News

No related news articles were found.

photocure asa (PHO) Related Businessweek News

No Related Businessweek News Found

photocure asa (PHO) Details

Photocure ASA is engaged in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment. The company markets Hexvix/Cysview for the detection of bladder cancer. Its products pipeline includes Visonac that has completed phase 2b study for the treatment of moderate to severe acne; Cevira, which has completed phase 2b study for the treatment of human papilloma virus disease and precancerous lesions of the cervix; and Lumacan that is under phase 1/2 development for the detection of colorectal cancer. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. The company operates in Norway, Sweden, Denmark, Finland, and the United States. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

Founded in 1997

photocure asa (PHO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

photocure asa (PHO) Key Developments

PhotoCure ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

PhotoCure ASA reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported sales revenue of NOK 24,771,000 against NOK 25,180,000 a year ago. Total revenues were NOK 25,957,000 against NOK 26,320,000 a year ago. Operating loss recurring was NOK 10,030,000 against NOK 19,362,000 a year ago. Loss before tax was NOK 5,384,000 against NOK 17,317,000 a year ago. Net loss for continued operations was NOK 23,431,000 against NOK 9,113,000 a year ago. Net loss for the year was NOK 23,431,000 or NOK 1.10 per undiluted and diluted share against NOK 9,156,000 or NOK 0.43 per undiluted and diluted share a year ago. Net cash flow used in operating activities was NOK 2,868,000 against NOK 17,771,000 a year ago. For the year, the company reported sales revenue of NOK 93,586,000 against NOK 79,307,000 a year ago. Total revenues were NOK 128,951,000 against NOK 83,616,000 a year ago. Operating loss recurring was NOK 5,631,000 against NOK 71,846,000 a year ago. Profit before tax was NOK 1,526,000 against loss before tax of NOK 66,852,000 a year ago. Net loss for continued operations was NOK 16,520,000 against NOK 58,648,000 a year ago. Net loss for the year was NOK 16,520,000 or NOK 0.77 per undiluted and diluted share against NOK 58,950,000 or NOK 2.78 per undiluted and diluted share a year ago. Net cash flow used in operating activities was NOK 6,089,000 against NOK 99,722,000 a year ago. Revenue increase was driven by continued market penetration of Hexvix/Cysview and a one-off termination payment of USD 5 million from Salix.

PhotoCure ASA, Q4 2014 Earnings Call, Feb 12, 2015

PhotoCure ASA, Q4 2014 Earnings Call, Feb 12, 2015

Photocure ASA Announces Conclusion of the Phase 2 Program, and FDA Clearance to Prepare Phase 3

Photocure ASA announced the conclusion of the Phase 2 program, and FDA clearance to prepare Phase 3 protocol for the clinical development of Cevira, the innovative breakthrough for the treatment of precancerous lesions of the cervix. The conclusion of a Phase 2 meeting with the FDA confirmed that the Phase 2 data supports the proposed Phase 3 program, and are sufficiently robust to continue the development of Cevira. Following a guidance meeting with FDA in December 2013, Photocure completed the re-analysis of the Phase 2b data as requested by the Agency. The re-analysis included a new panel read pathology assessment and applying new clinical success criteria in the end-point definition. The re- analysis demonstrated that Cevira provides improved treatment efficacy compared to placebo among patients with cervical high grade lesions (HSIL). Photocure discussed the results, including target population and statistical sample size, in the FDA meeting in December.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHO:NO 35.30 NOK -0.60

PHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHO.
View Industry Companies
 

Industry Analysis

PHO

Industry Average

Valuation PHO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOCURE ASA, please visit www.photocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.